目的探讨重组人血管内皮抑制素结合化疗治疗晚期非小细胞肺癌的近期临床疗效。方法选取2014年8月至2016年8月间河北省邢台市人民医院收治的90例晚期非小细胞肺癌患者,采用随机数表法分为观察组与对照组,每组45例,观察组患者在培美曲塞联合顺铂化疗基础上加用重组人血管内皮抑制素治疗,对照组患者给予培美曲塞联合顺铂化疗,比较两组患者近期疗效、外周血CD4~+、CD8~+T淋巴细胞亚群水平及干预后6个月的生活质量。结果观察组患者总有效率为75.6%高于对照组患者的总有效率62.2%,两组组间比较,差异有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后CD4~+升高,CD8~+降低,CD4~+/CD8~+升高,差异有统计学意义(P<0.05)。治疗后观察组患者CD4~+、CD8~+和CD4~+/CD8~+分别为(48.19±3.93)%、(28.56±5.34)%和(1.63±2.57),高于对照组患者的(44.51±4.21)%、(30.99±5.34)%和(1.40±2.23),差异均有统计学意义(均P<0.05)。与治疗前相比,两组患者治疗后生理状况、社会/家庭状况、情感状况和功能状况评分均升高,差异均有统计学意义(均P<0.05)。治疗后,观察组患者生理状况、社会/家庭状况、情感状况和功能状况评分分别为(25.72±3.90)分、(21.73±3.39)分、(20.56±3.23)分和(19.58±2.45)分,高于对照组患者的(22.56±3.93)分、(19.25±3.56)分、(18.64±3.30)分和(17.14±2.23)分,差异均有统计学意义(均P<0.05)。结论重组人血管内皮抑制素结合化疗治疗晚期非小细胞肺癌的近期临床疗效显著,能够改善患者免疫功能,提高患者生活质量。 Objective To investigate the recent clinical efficacy of recombinant human endostatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods Ninety patients with advanced non-small cell lung cancer admitted to Xingtai People’s Hospital of Hebei Province between August 2014 and August 2016 were randomly divided into observation group and control group with 45 cases in each group. Patients in observation group Pemetrexed combined with cisplatin plus the use of recombinant human endostatin on the basis of treatment, the control group of patients given pemetrexed combined with cisplatin chemotherapy, the two groups of patients with short-term efficacy, peripheral blood CD4 ~ +, CD8 ~ T lymphocyte subsets and quality of life 6 months after intervention. Results The total effective rate was 75.6% in the observation group and 62.2% in the control group. There was significant difference between the two groups (P <0.05). Compared with those before treatment, CD4 ~ +, CD8 ~ + and CD4 ~ + / CD8 ~ + increased after treatment in both groups, with statistical significance (P <0.05). (48.19 ± 3.93)%, (28.56 ± 5.34)% and (1.63 ± 2.57)% in the observation group were significantly higher than those in the control group (44.51 ± 4.21%, (30.99 ± 5.34)% and (1.40 ± 2.23), respectively (all P <0.05). Compared with before treatment, the two groups of patients after treatment physiological status, social / family status, emotional status and functional status scores were increased, the differences were statistically significant (P <0.05). After treatment, the scores of physiological status, social / family status, emotional status and functional status in the observation group were (25.72 ± 3.90) points, (21.73 ± 3.39) points, (20.56 ± 3.23) points and (19.58 ± 2.45) points respectively, (22.56 ± 3.93), (19.25 ± 3.56) points, (18.64 ± 3.30) points and (17.14 ± 2.23) points respectively in the control group. The difference was statistically significant (all P <0.05). Conclusion The recent clinical efficacy of recombinant human endostatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer is significant. It can improve the immune function and improve the quality of life of patients.